奥梅普拉诱导CYP3A4mRNA表达,但不诱导CYP3A4蛋白表达在肝细胞RG细胞中
Yuto Fujita1, Takahito Miyake1, Xinyan Shao1
1Department of Systems Biology, Graduate School of Pharmaceutical Sciences, Kyoto University.
Biological & pharmaceutical bulletin
|June 26, 2024
概括
药物相互作用是一个重大的临床挑战. 这项研究揭示了欧米醇增加了CYP3A4蛋白质降解,影响了超出mRNA水平的药物代谢.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
- 药物新陈代谢 药物新陈代谢
背景情况:
- 药物相互作用 (DDI) 限制了药物的有效性和安全性.
- 细胞染色体P450 (CYP) 酶,特别是CYP3A4和CYP1A2,在药物代谢和DDI中至关重要.
- 了解DDI机制对于安全的药物开发至关重要.
研究的目的:
- 使用HepaRG细胞调查潜在的DDI.
- 分析奥梅普拉和利芬素对CYP3A4和CYP1A2表达的作用.
- 探索DDI中的转录后调节.
主要方法:
- 使用人类HepaRG细胞作为一个体外模型.
- 在mRNA和蛋白质水平上评估CYP3A4和CYP1A2的表达.
- 进行了循环赫西米德追逐试验,以研究蛋白质降解.
主要成果:
- 奥梅普拉诱导了CYP1A2和CYP3A4mRNA,但并没有诱导CYP3A4蛋白.
- 奥梅普拉抑制了由皮辛诱导的CYP3A4蛋白质表达.
- 循环赫西米德追逐测定显示,梅醇增强了CYP3A4蛋白质降解.
结论:
- 奥梅普拉会影响CYP3A4蛋白质的稳定性,独立于mRNA诱导.
- DDI评估应包括翻译后的修改.
- 这突出了DDI的新机制,涉及蛋白质降解.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
371
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
371
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
421
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
421
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
399
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
399
Cell Specific Gene Expression
13.6K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.6K
Carrier-Mediated Transport
335
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
335
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
38
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
38


